Brief: Lipigon Pharmaceuticals Q2 Operating Loss Narrows To SEK 6.8 Million
24/11/2022 07:35
Nov 24 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST :
* Q2 OPERATING LOSS SEK 6.8 MILLION VERSUS LOSS SEK 11.5
MILLION
YEAR AGO
Further company coverage: LPGO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds